Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: Updated results of a multi-center, single-arm, phase 2 trial

被引：0
|
作者：
Zhao, Wensi
Li, Jun
Li, Liping
Huang, Junping
Gong, Wei
Yu, Xiongjie
Le, Kefa
He, Linli
Han, Qi
Wang, Songlin
Tang, Ze
Li, Wenbin
Hua, Xianliang
Chen, Yongshun
机构：
[1] Wuhan Univ, Renmin Hosp, Wuhan, Peoples R China
[2] Cent Hosp Xiao Gan, Dept Oncol, Xiaogan, Peoples R China
[3] Xiantao First Peoples Hosp, Xiantao, Peoples R China
[4] Jianghan Oilfield Gen Hosp, Qianjiang, Peoples R China
[5] Hubei Univ Art & Sci, Dept Oncol, Xiang Yang Cent Hosp, Xiangyang, Peoples R China
[6] Peoples Hosp Shiyan, Shiyan, Peoples R China
[7] Peoples Hosp Yangxin, Dept Oncol, Yangxin, Peoples R China
[8] First Peoples Hosp Tianmen City, Hubei Technol Coll, Dept Abdominal & Pelv Med Oncol, Affiliated Hosp, Tianmen, Peoples R China
[9] Xianning Cent Hosp, Xianning, Peoples R China
[10] Zhongxiang Peoples Hosp, Zhongxiang, Peoples R China
[11] Huangshi Cent Hosp, Dept Oncol, Huangshi, Hubei, Peoples R China
[12] Qianjiang Cent Hosp, Dept Oncol, Qianjiang, Peoples R China
[13] Wuhan Univ, Dept Clin Oncol, Renmin Hosp, Wuhan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3571
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Anlotinib combined with mXELIRI as second-line treatment in advanced colorectal cancer pretreated with bevacizumab plus standard chemotherapy: A single-arm, phase IB/II study
    Qu, Xin
    Chen, Xian
    Li, Yong
    Liu, Li-rong
    Qu, Yan-chun
    Hou, Fang-fang
    Li, Wen-zhu
    Liu, Yi-hong
    Zhu, Yan-juan
    Zhang, Haibo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [42] Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single-arm, multicenter, phase II study
    Tan, Sirui
    Zhang, Shunyu
    Zhou, Nan
    Cai, Xiaohong
    Yi, Cheng
    Gou, Hongfeng
    CANCER MEDICINE, 2023, 12 (24): : 22038 - 22046
  • [43] Gemcitabine plus nab-paclitaxel for second-line therapy of pancreatic cancer: A phase II, single-arm, multicenter study
    Huh, Gunn
    Choi, Jin Ho
    Lee, Sang Hyub
    Chun, Jung Won
    Cho, In Rae
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Lee, Hee Seung
    Bang, Seungmin
    ANNALS OF ONCOLOGY, 2021, 32 : S287 - S287
  • [44] Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial
    Li, Sheng
    Li, Xiaoyou
    Zhu, Qianni
    Gao, Jin
    Zhu, Chunrong
    Zhu, Liangjun
    CANCER CONTROL, 2024, 31
  • [45] Efficacy and safety of regorafenib plus biweekly TAS-102 for refractory metastatic colorectal cancer (REGTAS): A multicenter single-arm phase II trial
    Wang, Xiangling
    Li, Zhen
    Sha, Dan
    Ren, Haipeng
    Yi, Cuihua
    Li, Shuguang
    Wang, Peng
    Chu, Yunxia
    Wang, Jian
    Yang, Xiaorong
    Hao, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Surufatinib plus toripalimab and chemotherapy for second-line treatment of RAS/BRAF mutant (MT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC): A single-arm, phase II study (APHRODITE)
    Zhang, H.
    Liu, L.
    Zhu, X.
    Gao, Y.
    Tong, Z.
    Fu, Q.
    Bao, X.
    Dai, X.
    Zhao, P.
    Fang, W.
    Zheng, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S21 - S21
  • [47] Efficacy and safety of regorafenib in combination with chemotherapy as second-line therapy in patients with metastatic colorectal cancer: A network meta-analysis
    Xie, Xiaoyu
    Zhang, Jianwei
    Hu, Huabin
    Cai, Yue
    Wu, Zehua
    Ling, Jiayu
    Li, Weiwei
    Deng, Yanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [48] Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
    Zhu, J. L.
    Li, S.
    Zhu, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] Randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI plus bevacizumab versus FOLFIRI plus bevacizumab (AXEPT)
    Kim, T. W.
    Park, Y. S.
    Muro, K.
    Xu, R.
    Han, S.
    Yamazaki, K.
    Wang, W.
    Ahn, J. B.
    Uetake, H.
    Deng, Y.
    Cho, S.
    Matsumoto, H.
    Ba, Y.
    Lee, K-W.
    Nishina, T.
    Zhang, T.
    Iwasa, S.
    Morita, S.
    Sakamoto, J.
    ANNALS OF ONCOLOGY, 2017, 28 : 186 - 186
  • [50] Efficacy and safety of fruquintinib plus trifluridine/tipiracil (TAS-102) as third-line treatment in patients with metastatic colorectal adenocarcinoma: Results from a single arm, phase 2, multicenter study
    Peng, Jianjun
    Long, Jianting
    Huang, Ling
    Li, Yong
    Xiao, Jianjun
    Liu, Jianhua
    Zhang, Haibo
    Xie, Derong
    Wang, Wei
    Weng, Chengyin
    Zhang, Zongcheng
    Chai, Xiaoshu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345